OXPzero™ NSAIDs are novel salts of ibuprofen, naproxen, diclofenac and ketorolac, drugs commonly used to treat pain and inflammation. The OXPzero™ NSAIDs technology enables major growth opportunities in both over-the-counter and prescription medicine markets. Clinical results have already demonstrated these compounds reduce the gastrointestinal damage associated with conventional NSAIDs, without the need for complex formulation technologies or poly pharmacy approaches.
In addition, these compounds have very rapid absorption, without compromising safety, making them perfect for both acute and chronic pain markets.
OXProfen™
Our lead product OXProfen™ is a differentiated, superior form of ibuprofen delivering a range of benefits over standard ibuprofen. OXProfen™ has been proven to:
deliver major reduction in gastrointestinal (GI) mucosal damage on Rx dose: increase millions of usage occasions
significantly taste-mask the bitterness/burn of ibuprofen: opens up potential for new NPD and EPD pipeline
deliver an attractive PK profile bioequivalent to Ibuprofen free acid reference for AUC and Cmax, with faster Tmax
OXPZero™ Naproxen
NSAIDS are essential in the treatment of pain and inflammation but are affected by significant side effects, mainly GI and also CV risks. Naproxen is the preferred option for those in long term use given its lower CV risk profile but it requires careful patient management due to its GI safety profile.
OXPzero™ Naproxen is a novel salt of naproxen that offers the lower cardiovascular (CV) risk profile of naproxen with increased GI tolerance. OXPzero™ Naproxen is an immediate release, bioequivalent form to standard naproxen
Delivers the benefits of naproxen: safest CV risk profile in the category, long lasting pan relief and anti- inflammatory effect requiring less frequent dosing
Now with the lowest GI risk profile in the category, with reduced GI irritation confirmed in a Phase 1 proof-of-concept clinical tudy
Bioequivalent to immediate release standard naproxen
Tuneable release, could be adapted for fast onset while maintaining Cmax
OXPZero™ Ketorolac
There is an increasing demand for non-opioid analgesics in the surgery post-op and acute pain setting. Ketorolac is a potent NSAID, that produces analgesia similar to morphine, licensed for acute pain and used mainly in the post-operative setting. Due to the considerable GI side effects, the use of ketorolac is limited to 5 days in non high-risk populations.
OXPZero™ Ketorolac provides effective non-opioid pain relief but with a safer GI tract profile than standard ketorolac and allowing the formulation of multiple stable dosage forms including tablets, suspensions or nasal sprays.
If you are interested in learning more about our OXPzero™ NSAIDs pipeline and want to discuss partnership opportunities for your market, please contact us.